Discussion
high-grade, tumor, midline glioma
TUMOR
We propose to combine findings of neuropharmacokinetics, pharmacodynamics and genomic profiling in high-grade and diffuse midline glioma patients to provide a clearer understanding of the real-time changes within tumoral and peritumoral areas. These results are aimed at more intelligent selection of therapies that take into consideration the tumor biology, tumor microenvironment, and drug properties to measure treatment response. These studies will be the first use of clinical microdialysis as an experimental research tool in DMG patients (